BMS-986470, BMS-986470, N/A, BMS-986470
CA230-1019
Phase 2 small_molecule active
Quick answer
BMS-986470, BMS-986470, N/A, BMS-986470 for Sickle Cell Disease is a Phase 2 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Sickle Cell Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active